MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We hereby inform that the Company has scheduled a conference call for analysts and investors on Wednesday, February 14, 2024 at 04:00 p.m. on financial results for Q3FY24 MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for Considering And Approving Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31, 2023
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 ,inter alia, to consider and approve the unaudited financial results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2023 MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have received one request from our RTA for issue of duplicate share certificate the details of which have been attached MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have received intimation from our RTA on January 12, 2024 regarding duplicate share certificates of the Company the details oh which have been attached MARKSANS PHARMA LTD. - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for quarter ended December 31, 2023 has been attached herewith MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have received one request from shareholder for issue of duplicate share certificate on January 01, 2024 the details of which have been specified in the attachment MARKSANS PHARMA LTD. - 524404 - Closure of Trading Window
Intimation of closure of trading window MARKSANS PHARMA LTD. - 524404 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have received intimation from our RTA on December 21, 2023 regarding issuance of duplicate share certificates the details of which have been attached MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Credit Rating
We wish to inform you that India ratings & Research has upgraded the Company''s banking facilities ratings as per the attached file MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to regulation 30, please find enclosed the transcript of the investors / analysts meet for Q2FY2024 held on November 09, 2023